Generic Risk Disclosures and Item 303 Omissions: No Securities-Fraud Liability Without a Misleading Statement

Introduction

In Smith v. The Gap, Inc. (2d Cir. May 28, 2026), investors brought a putative securities class action against The Gap, Inc. (“Gap”) and two senior executives, alleging violations of § 10(b) and § 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The case centers on Gap’s August 2021 launch of “BODEQUALITY,” an Old Navy initiative to expand plus-size offerings in stores. According to the complaint, Gap overestimated demand for plus-size inventory, leading to surplus inventory, markdowns, and eventually a rollback of the program in stores. Gap later disclosed in a May 2022 Form 10-Q that quarterly results were negatively impacted in part by “execution missteps” related to BODEQUALITY.

The key legal issues on appeal were whether Gap’s risk-factor references, earnings-call remarks, and press releases were materially false or misleading due to alleged nondisclosure of BODEQUALITY problems; whether an alleged Item 303 omission could support a Rule 10b-5 claim; and whether plaintiffs adequately pleaded scienter under the PSLRA.

Summary of the Opinion

The Second Circuit affirmed the dismissal under Rule 12(b)(6), holding that: (1) the challenged statements were not materially false or misleading; (2) plaintiffs failed to plead scienter with particularity; and (3) without a primary violation, the § 20(a) control-person claim necessarily failed.

The court’s most consequential doctrinal clarifications concern (a) when risk disclosures can be misleading if a risk has “materialized,” (b) the limits of any “speak on one topic, disclose all related topics” theory, and (c) the post-Macquarie requirement that Item 303 omissions are actionable under Rule 10b-5 only if they render an affirmative statement misleading.

Analysis

Precedents Cited

  • City of Hialeah Emps.' Ret. Sys. v. Peloton Interactive, Inc., 153 F.4th 288 (2d Cir. 2025)
    Role in the opinion: Provided the elements of a § 10(b)/Rule 10b-5 claim and served as a comparator for when “hypothetical” risk warnings become misleading because the warned-of harm is effectively inevitable and known. The court distinguished this case by emphasizing that Gap’s challenged risk disclosures were generic, not framed as purely hypothetical, and did not include “offensive vs. defensive” mischaracterizations alleged in Peloton Interactive.
  • Altimeo Asset Mgmt. v. Qihoo 360 Tech. Co., 19 F.4th 145 (2d Cir. 2021)
    Role: Cited for the proposition that § 20(a) provides secondary liability for executives as controlling persons, and for the rule that absent a primary Exchange Act violation, a § 20(a) claim fails.
  • Rombach v. Chang, 355 F.3d 164 (2d Cir. 2004)
    Role: Supplied the contextual “reasonable investor” standard for misleadingness and the need to plead with specificity “why and how” statements are misleading. The court repeatedly used the “taken together and in context” framing to reject plaintiffs’ theory.
  • Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175 (2015)
    Role: Reinforced that investors read statements (including opinions) in context, including hedges and disclaimers—supporting the court’s reluctance to isolate risk-factor language from surrounding disclosures and the generic nature of the warnings.
  • Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011)
    Role: Provided the materiality “total mix” test and underscored that Rule 10b-5 does not impose a freestanding duty to disclose “any and all” material information—used to defeat plaintiffs’ “disclose one thing, therefore disclose everything” theory.
  • In re Vivendi, S.A. Sec. Litig., 838 F.3d 223 (2d Cir. 2016)
    Role: Anchored the principle that the securities laws generally do not require disclosure of all material information; rather, disclosure is required to prevent existing statements from being misleading.
  • Meyer v. Jinkosolar Holdings Co., 761 F.3d 245 (2d Cir. 2014)
    Role: Cited for the core “half-truth” principle: disclosure is required when necessary to make statements made not misleading.
  • Halperin v. eBanker USA.com, Inc., 295 F.3d 352 (2d Cir. 2002)
    Role: Supported dismissal by emphasizing that if “no reasonable investor could have been misled,” the claim fails—particularly relevant to generic risk disclosures about common industry problems.
  • Set Cap. LLC v. Credit Suisse Grp. AG, 996 F.3d 64 (2d Cir. 2021)
    Role: Used (along with Peloton Interactive) to clarify that risk disclosures can become misleading when defendants signal that they have “no reason to believe” the risk will materialize while knowing it is virtually certain. The court rejected plaintiffs’ attempt to turn Set Cap. LLC into a per se “materialized risk must be disclosed” rule.
  • Abramson v. Newlink Genetics Corp., 965 F.3d 165 (2d Cir. 2020)
    Role: Supported the holding that optimistic, qualitative characterizations (e.g., “strong” demand) can be unactionable puffery absent well-pleaded facts showing defendants disbelieved them.
  • Novak v. Kasaks, 216 F.3d 300 (2d Cir. 2000)
    Role: Played two roles: (1) on falsity, it supports the notion that officials need not present an “overly gloomy” picture so long as statements are consistent with reasonably available data; (2) on scienter, it requires plaintiffs alleging “access to contrary facts” to identify specific reports or statements containing the contradictory information.
  • IWA Forest Indus. Pension Plan v. Textron Inc., 14 F.4th 141 (2d Cir. 2021)
    Role: Reinforced pleading specificity: plaintiffs must explain “with specificity why and how” a statement is misleading (here, applied to a belatedly argued contention about whether the initiative “launched successfully”).
  • Macquarie Infrastructure Corp. v. Moab Partners, L.P., 601 U.S. 257 (2024)
    Role: Controlled the Item 303 analysis. The court applied Macquarie to hold that Item 303 nondisclosure cannot support a private Rule 10b-5(b) action unless the omission renders an affirmative statement misleading.
  • New England Carpenters Guaranteed Annuity & Pension Funds v. DeCarlo, 122 F.4th 28 (2d Cir. 2024)
    Role: Provided the two-track scienter framework: “motive and opportunity” or “strong circumstantial evidence of conscious misbehavior or recklessness.”
  • Slayton v. Am. Express Co., 604 F.3d 758 (2d Cir. 2010)
    Role: Emphasized that where motive and opportunity are not pleaded, circumstantial evidence must be “correspondingly greater.”
  • In re Scholastic Corp. Sec. Litig., 252 F.3d 63 (2d Cir. 2001)
    Role: Cited for the “knew facts or had access to non-public information contradicting their public statements” scienter concept, which plaintiffs failed to satisfy with sufficiently particularized allegations.
  • Tellabs, Inc. v. Makor Issues & Rts., Ltd., 551 U.S. 308 (2007)
    Role: Supplied the comparative inference test: the pleaded inference of scienter must be “cogent and at least as compelling as” a nonfraudulent inference. The court found the competing inference—localized issues rather than known nationwide failure—more plausible.
  • Gimpel v. Hain Celestial Grp., Inc., 156 F.4th 121 (2d Cir. 2025)
    Role: Framed the uncertain status of the “core operations doctrine” post-PSLRA and limited it to, at most, “supplemental support” rather than a standalone basis for scienter.
  • Diaz v. Gap, Inc., No. 22-cv-07371, 2025 WL 1293308 (E.D.N.Y. Mar. 31, 2025)
    Role: The district court decision under review; the Second Circuit affirmed its conclusions on falsity and scienter.

Legal Reasoning

1) Risk-factor disclosures: no per se “materialized risk” disclosure rule

Plaintiffs attacked Gap’s incorporation and repetition of earlier risk factors warning about misjudging demand, excess inventory, and markdowns, arguing it was misleading not to reveal BODEQUALITY-related problems if those risks had “materialized.” The court rejected a categorical rule. Instead, it applied a context-driven inquiry: a risk disclosure may be misleading if it would lead a reasonable investor to believe the risk had not yet occurred.

Critically, the court held that Gap’s warnings were generic and industry-ubiquitous (“misjudge the market,” discount excess inventory) and therefore would not plausibly communicate that Gap was not experiencing such issues at the time. Unlike Set Cap. LLC v. Credit Suisse Grp. AG and City of Hialeah Emps.' Ret. Sys. v. Peloton Interactive, Inc., Gap did not present the risk as merely hypothetical, did not assure investors it had “no reason to believe” the risk would occur, and even acknowledged it had not always predicted customer preferences accurately. That framing made it unreasonable to infer that investors were being told “this isn’t happening.”

2) Earnings-call optimism: puffery and data-consistency

The challenged earnings-call statements touted “strong” extended-size demand and customer interest. The court found two independent barriers to liability:

  • Puffery: Qualitative, optimistic characterizations like “strong” and “craving” were treated as inactionable under Abramson v. Newlink Genetics Corp., absent particularized allegations that the speaker disbelieved them.
  • Consistency with disclosed metrics: The executive cited quantifiable customer-file growth and new-customer figures; under Novak v. Kasaks, statements consistent with reasonably available data need not be “overly gloomy.”

3) Press releases: speaking about one cause does not mandate disclosure of all causes

Plaintiffs argued that once Gap attributed sales issues to supply-chain delays, it was required to disclose all other contributors, including BODEQUALITY-related issues. The court rejected this as “untenably overbroad,” relying on Matrixx Initiatives, Inc. v. Siracusano and the general “no affirmative duty to disclose everything” principle.

The holding is practical: a company may discuss one headwind (e.g., COVID-19 supply chain impacts) without automatically incurring a duty to narrate every internal operational issue unless omission of that additional information makes the spoken statement misleading.

4) Item 303: post-Macquarie, omissions are actionable only as “half-truths”

Plaintiffs invoked Item 303’s requirement to disclose known trends and uncertainties likely to materially affect sales or revenues. The court applied Macquarie Infrastructure Corp. v. Moab Partners, L.P. to hold that an Item 303 omission cannot support a private Rule 10b-5(b) claim unless it renders an affirmative statement misleading.

The court also emphasized pleading discipline under the PSLRA: plaintiffs attempted on appeal to tie Item 303 to a statement about “key initiatives” found in an exhibit attached to a motion to dismiss, but the statement “appears nowhere in the Complaint,” conflicting with the statutory requirement to specify each allegedly misleading statement.

Finally, even on the merits, describing BODEQUALITY as a “key initiative” intended to “expand customer reach” was not made misleading merely because the initiative later (or partially) performed poorly; an initiative can be “key” by strategy and investment even if it underdelivers.

5) Scienter: generalized “they must have known” allegations were insufficient

Because plaintiffs did not plead motive and opportunity, they needed stronger circumstantial evidence under New England Carpenters Guaranteed Annuity & Pension Funds v. DeCarlo and Slayton v. Am. Express Co.. The court found their scienter theory deficient for lack of particularity and for failing the Tellabs, Inc. v. Makor Issues & Rts., Ltd. comparative inference test.

  • Unspecified reports: Allegations that defendants “received reports” or “monitored inventory” lacked the Novak v. Kasaks details—who prepared them, when, what they said, and whether they actually tied problems to BODEQUALITY.
  • Secondhand store-level anecdotes: A confidential witness’s account of two store managers telling the CEO about size imbalances suggested at most localized issues, not knowledge of a nationwide failure, and did not contradict the public statements at the required level.
  • Competing nonfraud inference: The rollback in only 75 of 1,200 stores supported the inference that management initially believed issues were limited—an inference the court found at least as compelling as fraud.
  • Core operations doctrine: Citing Gimpel v. Hain Celestial Grp., Inc., the court treated the doctrine as, at most, supplemental and noted plaintiffs did not quantify BODEQUALITY’s importance to Gap’s core operations, undermining any attempt to impute knowledge.

Impact

Smith v. The Gap, Inc. reinforces several defense-significant and pleading-sensitive principles in Second Circuit securities litigation:

  • Risk factors are not automatically misleading when a risk “materializes”: plaintiffs must show that the disclosure’s context would lead a reasonable investor to believe the risk had not yet occurred—particularly where the warning is generic and industry-wide.
  • No “topic-by-topic completeness” requirement: discussing one cause of sales weakness does not obligate an issuer to disclose all other causes unless needed to avoid a misleading half-truth.
  • Item 303 claims are cabined by Macquarie: an Item 303 nondisclosure is not privately actionable under Rule 10b-5(b) absent a misleading affirmative statement.
  • Scienter remains the steep hill under the PSLRA: generalized assertions of access to information, unparticularized “reports,” and localized anecdotes will often fail under Novak and Tellabs.

Practically, the decision encourages plaintiffs to (a) plead specific contradictory internal documents, (b) link omissions to identifiable “statements made,” and (c) show how the challenged disclosure’s phrasing would affirmatively mislead a reasonable investor—rather than relying on hindsight and later disclosures.

Complex Concepts Simplified

  • Materially misleading (“half-truth”): A statement can be misleading not only if it is false, but if it is true yet incomplete in a way that creates the wrong impression. The law does not require companies to disclose everything—only what is needed so what they did say is not misleading.
  • Risk disclosures and “materialization”: Warning that something might happen can be misleading if the company implies it has not happened (or is unlikely), when in fact it already has happened or is virtually certain. But generic warnings about routine business risks typically do not signal that the risk is not currently occurring.
  • Puffery: Vague corporate optimism (“strong demand,” “successful”) is often not actionable because reasonable investors do not treat it as a concrete factual promise—unless plaintiffs can plead facts showing the speaker knew it was false.
  • Item 303: An SEC disclosure rule requiring discussion of known trends/uncertainties in certain filings. After Macquarie, failing to comply with Item 303 does not automatically create a private fraud claim; it matters only if it makes another statement misleading.
  • Scienter: The intent to deceive (or reckless disregard). Under the PSLRA, plaintiffs must plead particular facts supporting a “strong inference” of scienter, and courts compare innocent explanations against the alleged fraudulent one.
  • Core operations doctrine: A theory that top executives “must have known” important facts about the company’s central business. In the Second Circuit, it is at most supplemental and generally cannot substitute for particularized allegations of what defendants knew and when.

Conclusion

Smith v. The Gap, Inc. is a modern Second Circuit application of contextual misleadingness, Macquarie’s Item 303 limitation, and stringent PSLRA scienter pleading. The court refused to convert later-acknowledged operational missteps into earlier fraud absent a pleaded misleading statement and a strong, particularized inference of intent or recklessness.

The central takeaway is doctrinal and practical: securities-fraud liability turns on misleading speech (or half-truths), not on imperfect business execution. Generic risk warnings, non-exhaustive explanations of performance, and strategic optimism—without specific, contradictory facts showing deception—are unlikely to sustain a Rule 10b-5 claim in the Second Circuit.